
Type2 Diabetes Mellitus- Pipeline Insight, 2024
Description
Type2 Diabetes Mellitus- Pipeline Insight, 2024
DelveInsight’s, “Type2 Diabetes Mellitus- Pipeline Insight, 2024,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type2 Diabetes mellitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Type2 Diabetes Mellitus: Overview
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type2 and Gestational Diabetes. Type 2 diabetes mellitus (T2DM) accounts for around 90% of all cases of diabetes. In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM. T2DM is most commonly seen in persons older than 45 years. Type 2 diabetes primarily occurs as a result of obesity and lack of exercise. Some people are more genetically at risk than others. Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10% due primarily to type 1 diabetes and gestational diabetes. Diagnosis of diabetes is by blood tests such as fasting plasma glucose, oral glucose tolerance test, or glycated hemoglobin (A1C). Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.
""Type2 Diabetes Mellitus- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type2 Diabetes Mellitus pipeline landscape is provided which includes the disease overview and Type2 Diabetes Mellitus treatment guidelines. The assessment part of the report embraces, in depth Type2 Diabetes Mellitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type2 Diabetes Mellitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type2 Diabetes mellitus R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.
This segment of the Type2 Diabetes mellitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type2 Diabetes mellitus Emerging Drugs
- Sotagliflozin: Lexicon Pharmaceuticals
- ORMD0801: Oramed Pharmaceuticals
- LY3209590-Eli lily and Company
- HM12460A: Hanmi Pharmaceuticals
- HM14220:Hanmi Pharmaceuticals
Further product details are provided in the report……..
Type2 Diabetes mellitus: Therapeutic Assessment
This segment of the report provides insights about the different Type2 Diabetes mellitus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Type2 Diabetes mellitus
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Type2 Diabetes mellitus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type2 Diabetes mellitus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type2 Diabetes mellitus drugs.
Type2 Diabetes mellitus Report Insights
- Type2 Diabetes mellitus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Type2 Diabetes mellitus drugs?
- How many Type2 Diabetes mellitus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type2 Diabetes mellitus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type2 Diabetes mellitus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type2 Diabetes mellitus and their status?
- What are the key designations that have been granted to the emerging drugs?
- Hanmi Pharmaceuticals
- Sanofi
- Eli lily and Company
- AstraZeneca
- NovoNordisk
- Noxxon Pharma AG
- Oramed Pharmaceuticals
- Lexicon Pharmaceuticals
- Daiichi Sankyo Company
- Halozyme Therapeutics
- Saniona
- Novartis
- Pfizer
- Merck Sharp & Dohme Corp.
- Mylan
- Nordic Bioscience A/S
- KeyBioscience AG
- Adocia
- Jiangsu Hengrui Medicine
- Bristol myers Suibb
- Phenomix
- Forest Laboratories
- ACADIA Pharmaceuticals
- Hanmi Pharmaceuticals
- Cytogel
- Ligand Pharmaceuticals
- Arthritis Innovation Corporation
- Astellas Pharma
- IItoo Pharma
- Medspace Inc.
- Oramed Ltd.
- Flexion Therapeutics
- Integrium
- AbbVie
- ORMD0801
- HumalogU-100
- Sotagliflozin
- Exenatide
- Topiramate
- LY3209590
- HM12460A
- HM14220
- Tesofensine/Metoprolol
- Ruboxistaurin Mesylate
- BMS-816336
- Atrasentan
- Inhaled Human Insulin
- Human regular U-500 insulin
- Humalog
- Insulin Glargine
- Tirzepatide
- Oxyntomodulin
Table of Contents
100 Pages
- Introduction
- Executive Summary
- Type2 Diabetes mellitus: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Type2 Diabetes mellitus – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Sotagliflozin: Lexicon Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- LY3209590: Eli lily and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- HM12460A: Hanmi Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- HM14220: Hanmi Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Type2 Diabetes mellitus- Key Companies
- Type2 Diabetes mellitus- Key Products
- Type2 Diabetes mellitus - Unmet Needs
- Type2 Diabetes mellitus - Market Drivers and Barriers
- Type2 Diabetes mellitus - Future Perspectives and Conclusion
- Type2 Diabetes mellitus Analyst Views
- Type2 Diabetes mellitus Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.